; and (B) with respect to claims for reimbursement submitted otherwise, 30 days. (3) Insulin drug The term insulin drug means a medication approved by the Food and Drug Administration to treat high blood glucose. (4) Manufacturer The term manufacturer means, with respect to insulin drugs, any entity which is engaged in the production, preparation, propagation, compounding, conversion, or processing of prescription drug products, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis. Such term does not include a wholesale distributor of insulin drugs or a retail pharmacy licensed under State law. (5) Medicaid price (A) In general The term Medicaid price means, with respect to an individual entitled to medical assistance under title XIX, the net receipt specified in subparagraph (B) for the dosage form and strength of an insulin drug and any increase due to a certification described in subsection (b)(1)(B)(ii)(I). (B) Net receipt specified For purposes of subparagraph (A), the net receipt specified in this subparagraph shall be equal to the product of— (i) the total number of units of each dosage form and strength purchased under the program in the rebate period (as determined by the Secretary), and (ii) the amount that is the list price of such drug during such rebate period, less, the total amount of rebates that the manufacturer paid with respect to such drug during such rebate period. (6) Negotiated price The term negotiated price has the meaning given such term in section 423.100 of title 42, Code of Federal Regulations (as in effect on the date of enactment of this section), except that such negotiated price shall not include any dispensing fee for the applicable drug. . 3. Maintenance of effort throughout the insulin supply chain (a) Elimination of PBM rebates Section 1128B(b)(3) of the Social Security Act (42 U.S.C. 1320a–7b(b)(3)) is amended— (1) in subparagraph (E), by